Psychedelics Should Be Protected for the Sake of Humanity
There’s a specific moment I want you to sit with. A Wall Street analyst is modeling peak annual sales for a pill made of LSD. Not “acid,” not a sacrament, not the compound that a Swiss chemist accidentally absorbed through his fingertips in 1943 and then rode a bicycle home on, tripping, because that’s a true story and I never tire of it. A pill. With a ticker symbol. With a total addressable market.
That’s not a hypothetical. It’s happening right now, and it’s the reason I think this conversation needs to happen before the market finishes writing the rules for us.
Definium Therapeutics, the company formerly known as MindMed, trades on the Nasdaq as DFTX. Its lead asset, DT120, is an orally disintegrating tablet of pharmaceutically formulated LSD. In 2026 alone, it has delivered three consecutive positive Phase 3 trial results: major depressive disorder in June, generalized anxiety disorder in August, and a second GAD trial in September, with a placebo-adjusted 8.1-point improvement on a standard depression scale that held up at both six and twelve weeks. Wall Street analysts are now modeling $1.5 to $2 billion in peak annual sales for major depression alone, with additional billions projected across anxiety and a coming PTSD trial.
I want to be fair to what this actually represents, because I’m not interested in being reflexively anti-pharma for the sake of a clean narrative. These trials, if they hold up through FDA review, could genuinely help people with treatment-resistant depression and anxiety who have exhausted SSRIs. That’s not nothing. I’m not going to pretend a rigorously tested, precisely dosed medical product is worthless just because it comes from a company with a stock price.
But here’s what changed the temperature on all of this: on April 18, 2026, President Trump signed Executive Order 14401, directing the FDA to fast-track review of psychedelic compounds and cutting the standard ten-to-twelve-month review down to as little as one to two months via “National Priority Vouchers.” Compass Pathways, Usona Institute, and Transcend Therapeutics all received these vouchers within a week of the order. The federal government is now actively accelerating the exact companies best positioned, by capital and patent portfolio, to own this space first.
You don’t have to speculate about what happens when a formerly criminalized plant medicine gets folded into regulated commerce, because cannabis just showed us, in real time, over the last decade.
The honest data on legal cannabis is not the utopia the industry markets. Only 24.4 percent of U.S. cannabis operators are profitable on an after-tax basis, compared to 65 percent of ordinary small businesses, largely because federal tax code Section 280E still denies cannabis businesses standard deductions since it remains federally scheduled. Twenty-three states saw regulated sales decline in 2025, and more than 4,000 cannabis businesses surrendered their licenses over an 18-month span. The people getting squeezed out are disproportionately the small operators and social-equity licensees the reform movement promised to lift up; the capital-heavy multistate operators are the ones positioned to acquire distressed licenses and consolidate.
I’m not telling you this to say legalization was a mistake. Article one of this series lays out why prohibition’s costs were worse. I’m telling you this because it’s the honest preview of what happens to a substance once industry, not culture or community, becomes its primary steward: consolidation toward whoever has the deepest balance sheet, regardless of whether that serves the people who most need access.
Cannabis is a commodity crop; anyone can grow it once it’s legal, which is part of why margins collapsed. Psychedelics are different, because pharmaceutical formulations can be patented, and the patent fights are already ugly.
Compass Pathways has spent years building a patent portfolio around synthetic psilocybin, including a filing that claimed methods of administering psilocybin in a room with muted colors, soft furniture, and a therapist holding the patient’s hand, according to Harvard Law Review’s analysis. Critics, including the nonprofit patent watchdog Freedom to Operate, argue these claims describe practices used for decades in Indigenous ceremonies and underground therapy, not genuine inventions. Freedom to Operate spent roughly a million dollars and months of expert work challenging two of Compass’s psilocybin patents at the U.S. Patent Trial and Appeal Board. They lost. The board’s ruling was narrow enough that it may open some space for competitors, but the broader lesson stands: contesting an overly broad patent is expensive, slow, and not guaranteed to work, and Compass has already secured a coveted FDA Breakthrough Therapy designation on top of it.
A patent attorney quoted in Vice’s reporting on the fight put it plainly: whoever ends up holding these patents can dictate use, either through licensing revenue or by choosing who gets to compete at all. That is precisely the “consolidation in a few hands” outcome you’re worried about, and it isn’t speculative. It’s the current legal battlefield, actively being fought over compounds derived from mushrooms that have been used by humans for millennia before anyone thought to file paperwork on them.
To be fair to the other side of this, access isn’t purely closing. Oregon and Colorado both operate legal, regulated, non-pharmaceutical psilocybin programs, entirely outside the patent-and-pharma pipeline. Colorado’s Natural Medicine Health Act, passed by voters in 2022, has licensed 34 healing centers as of early 2026, including lower-cost “micro-healing center” tiers designed specifically to keep access affordable, and the program allows adults 21 and older from any state to participate without a medical diagnosis or referral. Colorado’s law may expand to cover DMT, ibogaine, and mescaline (excluding peyote) starting in 2026. This is a genuine, functioning model of legal psychedelic access that exists entirely apart from a pharmaceutical company’s balance sheet, and it deserves more attention than it gets.
There’s also a religious-liberty precedent worth knowing, because it’s the strongest existing legal foundation for the human-rights framing you’re reaching for. In Gonzales v. O Centro Espirita Beneficente Uniao do Vegetal (2006), the Supreme Court ruled unanimously, 8-0, that the federal government could not bar a small Brazil-based church from using DMT-containing ayahuasca tea in its ceremonies, because the Religious Freedom Restoration Act required the government to show a compelling interest and it hadn’t. That’s not a blanket right to psychedelics for anyone who wants one. It’s a real, binding legal recognition that sincere spiritual use of a Schedule I compound can outweigh a blanket prohibition, decided by a court that included some of the most conservative justices in modern history. If you’re looking for the legal seed of “entheogen use as protected practice,” that case is it, and it’s been sitting there, mostly unused as a broader template, for two decades.
I don’t think the fix is stopping pharmaceutical psychedelic research. Compass and Definium’s trial data, if it survives replication and full FDA review, could genuinely help people who’ve run out of options on standard antidepressants, and blocking that on principle would be its own kind of cruelty.
What I think has to happen in parallel, and hasn’t, is protecting the non-pharmaceutical, non-patentable path at the same time the pharma path accelerates: expanding Oregon- and Colorado-style regulated access, protecting religious and Indigenous ceremonial use the way O Centro already established is constitutionally possible, and watching the patent office closely enough that “administering a drug in a room with soft furniture” doesn’t become somebody’s twenty-year monopoly. Cannabis showed us what happens when we let one path, the industrial one, become the only path: consolidation, margin compression for everyone except the biggest players, and a slower reckoning with the people prohibition actually hurt. I don’t want to watch that movie twice, just with a stronger compound and a faster FDA clock.
You called psychedelics a technology for altering consciousness that predates every institution now racing to patent it. I don’t think that’s mysticism. I think it’s just a fact about the timeline, and the timeline is the argument.
First Amendment Encyclopedia, Gonzales v. O Centro Espirita Beneficente Uniao do Vegetal
CANNABIS AND PSYCHEDELICS, READ ON…
